These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 30882478

  • 21. Nebulized Versus IV Amikacin as Adjunctive Antibiotic for Hospital and Ventilator-Acquired Pneumonia Postcardiac Surgeries: A Randomized Controlled Trial.
    Hassan NA, Awdallah FF, Abbassi MM, Sabry NA.
    Crit Care Med; 2018 Jan; 46(1):45-52. PubMed ID: 28857848
    [Abstract] [Full Text] [Related]

  • 22. Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia.
    Motos A, Li Bassi G, Pagliara F, Fernandez-Barat L, Yang H, Aguilera Xiol E, Senussi T, Idone FA, Travierso C, Chiurazzi C, Amaro R, Yang M, Bobi J, Rigol M, Nicolau DP, Frigola G, Cabrera R, Ramirez J, Pelosi P, Blasi F, Antonelli M, Artigas A, Vila J, Kollef M, Torres A.
    Antimicrob Agents Chemother; 2021 Jan 20; 65(2):. PubMed ID: 33168605
    [Abstract] [Full Text] [Related]

  • 23. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
    Riou M, Carbonnelle S, Avrain L, Mesaros N, Pirnay JP, Bilocq F, De Vos D, Simon A, Piérard D, Jacobs F, Dediste A, Tulkens PM, Van Bambeke F, Glupczynski Y.
    Int J Antimicrob Agents; 2010 Dec 20; 36(6):513-22. PubMed ID: 20926262
    [Abstract] [Full Text] [Related]

  • 24. Aerosolized antibiotics in mechanically ventilated patients: delivery and response.
    Palmer LB, Smaldone GC, Simon SR, O'Riordan TG, Cuccia A.
    Crit Care Med; 1998 Jan 20; 26(1):31-9. PubMed ID: 9428540
    [Abstract] [Full Text] [Related]

  • 25. Fosfomycin in severe infections due to genetically distinct pan-drug-resistant Gram-negative microorganisms: synergy with meropenem.
    Perdigão Neto LV, Oliveira MS, Martins RCR, Marchi AP, Gaudereto JJ, da Costa LATJ, de Lima LFA, Takeda CFV, Costa SF, Levin AS.
    J Antimicrob Chemother; 2019 Jan 01; 74(1):177-181. PubMed ID: 30376073
    [Abstract] [Full Text] [Related]

  • 26. Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
    Avery LM, Sutherland CA, Nicolau DP.
    J Med Microbiol; 2019 Jun 01; 68(6):893-897. PubMed ID: 31050629
    [Abstract] [Full Text] [Related]

  • 27. Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens.
    Montgomery AB, Rhomberg PR, Abuan T, Walters KA, Flamm RK.
    Antimicrob Agents Chemother; 2014 Jul 01; 58(7):3714-9. PubMed ID: 24752275
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa.
    Oshima K, Nakamura S, Iwanaga N, Takemoto K, Miyazaki T, Yanagihara K, Miyazaki Y, Mukae H, Kohno S, Izumikawa K.
    Antimicrob Agents Chemother; 2017 Jan 01; 61(1):. PubMed ID: 27799201
    [Abstract] [Full Text] [Related]

  • 29. A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial.
    Kollef MH, Ricard JD, Roux D, Francois B, Ischaki E, Rozgonyi Z, Boulain T, Ivanyi Z, János G, Garot D, Koura F, Zakynthinos E, Dimopoulos G, Torres A, Danker W, Montgomery AB.
    Chest; 2017 Jun 01; 151(6):1239-1246. PubMed ID: 27890714
    [Abstract] [Full Text] [Related]

  • 30. Activity of colistin alone or in combination with rifampicin or meropenem in a carbapenem-resistant bioluminescent Pseudomonas aeruginosa intraperitoneal murine infection model.
    Cai Y, Yang D, Wang J, Wang R.
    J Antimicrob Chemother; 2018 Feb 01; 73(2):456-461. PubMed ID: 29149302
    [Abstract] [Full Text] [Related]

  • 31. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.
    Ehsan Z, Clancy JP.
    Future Microbiol; 2015 Feb 01; 10(12):1901-12. PubMed ID: 26573178
    [Abstract] [Full Text] [Related]

  • 32. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J, Benavent E, Sierra Y, El Haj C, Soldevila L, Torrejón B, Rigo-Bonnin R, Tubau F, Ariza J, Murillo O.
    Int J Antimicrob Agents; 2019 May 01; 53(5):612-619. PubMed ID: 30682497
    [Abstract] [Full Text] [Related]

  • 33. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W, Crandon JL, Hamada Y, Nicolau DP.
    J Antimicrob Chemother; 2016 Feb 01; 71(2):428-37. PubMed ID: 26559690
    [Abstract] [Full Text] [Related]

  • 34. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y, Kobayashi Y.
    Jpn J Antibiot; 2007 Dec 01; 60(6):394-403. PubMed ID: 18447209
    [Abstract] [Full Text] [Related]

  • 35. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.
    Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A, Golmard JL, Rouby JJ, Nebulized Antibiotics Study Group.
    Anesthesiology; 2012 Dec 01; 117(6):1335-47. PubMed ID: 23132092
    [Abstract] [Full Text] [Related]

  • 36. Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.
    Louie A, Liu W, VanGuilder M, Neely MN, Schumitzky A, Jelliffe R, Fikes S, Kurhanewicz S, Robbins N, Brown D, Baluya D, Drusano GL.
    J Infect Dis; 2015 Apr 15; 211(8):1326-33. PubMed ID: 25362196
    [Abstract] [Full Text] [Related]

  • 37. Nebulized Antibiotics for Multidrug-Resistant Ventilator-Associated Pseudomonas aeruginosa Pneumonia.
    Gilbert DN.
    Crit Care Med; 2019 Jun 15; 47(6):880-881. PubMed ID: 31095023
    [No Abstract] [Full Text] [Related]

  • 38. Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa.
    Lin Y, Chang RYK, Britton WJ, Morales S, Kutter E, Chan HK.
    Int J Pharm; 2018 Nov 15; 551(1-2):158-165. PubMed ID: 30223075
    [Abstract] [Full Text] [Related]

  • 39. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets.
    Goldstein I, Wallet F, Nicolas-Robin A, Ferrari F, Marquette CH, Rouby JJ.
    Am J Respir Crit Care Med; 2002 Nov 15; 166(10):1375-81. PubMed ID: 12406838
    [Abstract] [Full Text] [Related]

  • 40. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.
    Tessier F, Quentin C.
    Eur J Clin Microbiol Infect Dis; 1997 Feb 15; 16(2):159-62. PubMed ID: 9105845
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.